| Cisplatin + RT for Triple Negative Breast Cancer (NCT01674842) | Dana-Farber Cancer Institute | 2012-10-01 |
| Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer (NCT01623349) | Dana-Farber Cancer Institute | 2012-09-01 |
| Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas (NCT01663090) | Dana-Farber Cancer Institute | 2012-09-01 |
| Whole-Exome Sequencing (WES) of Cancer Patients (NCT02127359) | Dana-Farber Cancer Institute | 2012-09-01 |
| Healthy Directions After Lung Surgery Pilot (NCT02135211) | Dana-Farber Cancer Institute | 2012-09-01 |
| Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer (NCT01661868) | Dana-Farber Cancer Institute | 2012-08-01 |
| iCAT for Recurrent/Refractory/HR Solid Tumors (NCT01853345) | Dana-Farber Cancer Institute | 2012-08-01 |
| Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (NCT01466036) | Dana-Farber Cancer Institute | 2012-07-01 |
| Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer (NCT01647607) | Dana-Farber Cancer Institute | 2012-06-01 |
| Ruxolitinib in Patients With Breast Cancer (NCT01562873) | Dana-Farber Cancer Institute | 2012-06-01 |
| Fulvestrant With or Without Ganetespib in HR+ Breast Cancer (NCT01560416) | Dana-Farber Cancer Institute | 2012-06-01 |
| SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (NCT01574274) | Dana-Farber Cancer Institute | 2012-06-01 |
| Serious Illness Communication Project (NCT01786811) | Dana-Farber Cancer Institute | 2012-06-01 |
| BKM120 For Triple Negative Breast Cancer (NCT01790932) | Dana-Farber Cancer Institute | 2012-06-01 |
| Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia (NCT01614821) | Dana-Farber Cancer Institute | 2012-05-01 |
| Study of Vitamin D in Untreated Metastatic Colorectal Cancer (NCT01516216) | Dana-Farber Cancer Institute | 2012-04-13 |
| XL-184+Abiraterone in Post-Chemo CRPC (NCT01574937) | Dana-Farber Cancer Institute | 2012-04-03 |
| Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO) (NCT02057432) | Dana-Farber Cancer Institute | 2012-04-01 |
| Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma (NCT01484314) | Dana-Farber Cancer Institute | 2012-04-01 |
| Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes (NCT02950987) | Dana-Farber Cancer Institute | 2012-03-01 |
| Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy (NCT01568346) | Dana-Farber Cancer Institute | 2012-02-01 |
| HKI-272 for HER2-Positive Breast Cancer and Brain Metastases (NCT01494662) | Dana-Farber Cancer Institute | 2012-02-01 |
| Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL (NCT01465334) | Dana-Farber Cancer Institute | 2011-12-01 |
| Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma (NCT01586182) | Dana-Farber Cancer Institute | 2011-11-01 |
| Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL (NCT01523977) | Dana-Farber Cancer Institute | 2011-11-01 |
| Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia (NCT01470196) | Dana-Farber Cancer Institute | 2011-10-01 |
| RPFNA Assessment of Exercise Effect in Breast Cancer (NCT01961128) | Dana-Farber Cancer Institute | 2011-10-01 |
| Dasatinib in Advanced Squamous Cell Lung Cancer (NCT01491633) | Dana-Farber Cancer Institute | 2011-09-01 |
| Promoting Organizational Capacity to Implement Cancer Control Programs Among Latino Churches (NCT01740219) | Dana-Farber Cancer Institute | 2011-09-01 |
| STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma (NCT01551693) | Dana-Farber Cancer Institute | 2011-09-01 |
| Image-Guided Gynecologic Brachytherapy (NCT01399658) | Dana-Farber Cancer Institute | 2011-09-01 |
| A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors (NCT02133625) | Dana-Farber Cancer Institute | 2011-08-01 |
| The Preoperative Health & Body Study (NCT01516190) | Dana-Farber Cancer Institute | 2011-08-01 |
| Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease (NCT01366092) | Dana-Farber Cancer Institute | 2011-07-01 |
| Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study (NCT01221753) | Dana-Farber Cancer Institute | 2011-07-01 |
| Methylphenidate for Cancer-Related Fatigue (NCT01164956) | Dana-Farber Cancer Institute | 2011-07-01 |
| Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors (NCT01323920) | Dana-Farber Cancer Institute | 2011-05-01 |
| Exercise and Metformin in Colorectal and Breast Cancer Survivors (NCT01340300) | Dana-Farber Cancer Institute | 2011-05-01 |
| Socialization of Adult Men With Congenital Hemophilia A or B (NCT01510418) | Dana-Farber Cancer Institute | 2011-05-01 |
| The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study (NCT02390414) | Dana-Farber Cancer Institute | 2011-05-01 |
| Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate (NCT01319591) | Dana-Farber Cancer Institute | 2011-03-01 |
| Pilot Study for Young Women's Intervention (NCT01647594) | Dana-Farber Cancer Institute | 2011-03-01 |
| Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT (NCT01286675) | Dana-Farber Cancer Institute | 2011-03-01 |
| CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer (NCT01191697) | Dana-Farber Cancer Institute | 2011-02-01 |
| Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer (NCT01184326) | Dana-Farber Cancer Institute | 2011-01-01 |
| Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer (NCT01273805) | Dana-Farber Cancer Institute | 2011-01-01 |
| Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer (NCT01222572) | Dana-Farber Cancer Institute | 2010-12-01 |
| Amgen 386 for Recurrent Glioblastoma (NCT01290263) | Dana-Farber Cancer Institute | 2010-12-01 |
| Trastuzumab and Vinorelbine in Advanced Breast Cancer (NCT01185509) | Dana-Farber Cancer Institute | 2010-11-01 |
| Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease (NCT01226420) | Dana-Farber Cancer Institute | 2010-10-01 |
| Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro (NCT01472627) | Dana-Farber Cancer Institute | 2010-10-01 |
| SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) (NCT01402687) | Dana-Farber Cancer Institute | 2010-10-01 |
| STA-9090(Ganetespib) in Metastatic Ocular Melanoma (NCT01200238) | Dana-Farber Cancer Institute | 2010-09-17 |
| Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease (NCT01221766) | Dana-Farber Cancer Institute | 2010-09-01 |
| NIR-Guided Sentinel Lymph Node Mapping in Melanoma (NCT01121718) | Dana-Farber Cancer Institute | 2010-09-01 |
| Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer (NCT00925652) | Dana-Farber Cancer Institute | 2010-09-01 |
| Enhancing Adherence and Knowledge of Erlotinib in Patients Wtih Non-Small Cell Lung Cancer (NCT01378598) | Dana-Farber Cancer Institute | 2010-09-01 |
| FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer (NCT01243619) | Dana-Farber Cancer Institute | 2010-08-01 |
| Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer (NCT01253369) | Dana-Farber Cancer Institute | 2010-06-01 |
| Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia (NCT01125293) | Dana-Farber Cancer Institute | 2010-04-01 |
| Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease (NCT01085201) | Dana-Farber Cancer Institute | 2010-04-01 |
| AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors (NCT01024387) | Dana-Farber Cancer Institute | 2010-03-01 |
| Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT01066663) | Dana-Farber Cancer Institute | 2010-03-01 |
| Panobinostat (LBH589) in Patients With Metastatic Melanoma (NCT01065467) | Dana-Farber Cancer Institute | 2010-02-01 |
| RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer (NCT01058408) | Dana-Farber Cancer Institute | 2010-02-01 |
| RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer (NCT01058655) | Dana-Farber Cancer Institute | 2010-02-01 |
| Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders (NCT01177527) | Dana-Farber Cancer Institute | 2009-12-30 |
| Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer (NCT00889187) | Dana-Farber Cancer Institute | 2009-12-01 |
| Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases (NCT01004172) | Dana-Farber Cancer Institute | 2009-11-01 |
| Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia (NCT00976248) | Dana-Farber Cancer Institute | 2009-11-01 |
| Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease (NCT01000155) | Dana-Farber Cancer Institute | 2009-10-01 |
| Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer (NCT00953576) | Dana-Farber Cancer Institute | 2009-09-29 |
| Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT (NCT01664091) | Dana-Farber Cancer Institute | 2009-09-01 |
| LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia (NCT00936611) | Dana-Farber Cancer Institute | 2009-07-01 |
| RAD001 for Patients With Radioiodine Refractory Thyroid Cancer (NCT00936858) | Dana-Farber Cancer Institute | 2009-07-01 |
| Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer (NCT00911820) | Dana-Farber Cancer Institute | 2009-07-01 |
| Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (NCT00942682) | Dana-Farber Cancer Institute | 2009-07-01 |
| Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma (NCT00928018) | Dana-Farber Cancer Institute | 2009-06-01 |
| Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas (NCT00782626) | Dana-Farber Cancer Institute | 2009-06-01 |
| Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma (NCT00903968) | Dana-Farber Cancer Institute | 2009-06-01 |
| Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer (NCT00910000) | Dana-Farber Cancer Institute | 2009-06-01 |
| Extended Endocrine Therapy for Premenopausal Women With Breast Cancer (NCT00903162) | Dana-Farber Cancer Institute | 2009-05-01 |
| A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (NCT00834093) | Dana-Farber Cancer Institute | 2009-04-01 |
| Multiple Risk Behavior Intervention in Health Care Settings (NCT01415492) | Dana-Farber Cancer Institute | 2009-03-01 |
| Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies (NCT00973440) | Dana-Farber Cancer Institute | 2009-03-01 |
| Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma (NCT00790010) | Dana-Farber Cancer Institute | 2009-02-26 |
| Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer (NCT00264602) | Dana-Farber Cancer Institute | 2009-02-18 |
| Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies (NCT00856180) | Dana-Farber Cancer Institute | 2009-02-01 |
| Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma (NCT00856050) | Dana-Farber Cancer Institute | 2009-02-01 |
| Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin (NCT00831571) | Dana-Farber Cancer Institute | 2009-02-01 |
| Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma (NCT00788775) | Dana-Farber Cancer Institute | 2009-01-23 |
| Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease (NCT00815919) | Dana-Farber Cancer Institute | 2008-12-01 |
| Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma (NCT00808639) | Dana-Farber Cancer Institute | 2008-12-01 |
| A Pilot Study of Acupuncture Treatment for Dysphagia (NCT00797732) | Dana-Farber Cancer Institute | 2008-12-01 |
| Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation (NCT00809250) | Dana-Farber Cancer Institute | 2008-11-01 |
| Computerized Assessment for Patients With Cancer (NCT00852852) | Dana-Farber Cancer Institute | 2008-10-01 |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (NCT00804336) | Dana-Farber Cancer Institute | 2008-10-01 |
| Collection and Banking of Leukemia Cells MDS/AML (NCT00809367) | Dana-Farber Cancer Institute | 2008-10-01 |
| Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy (NCT00776594) | Dana-Farber Cancer Institute | 2008-10-01 |
| Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma (NCT00768144) | Dana-Farber Cancer Institute | 2008-09-01 |